Amphetamines promote weight loss primarily by suppressing appetite and increasing the body’s energy expenditure, effects driven by their ability to flood the brain with catecholamines like dopamine and norepinephrine. These drugs were among the first pharmaceutical tools ever marketed for obesity, and they do work in the short term. But the story of amphetamine-based weight loss is also a story of tolerance, cardiovascular strain, psychological dependence, and dramatic rebound weight gain, which is why most amphetamines are no longer approved or recommended for long-term obesity treatment.
How Amphetamines Reduce Body Weight
Amphetamines act on several brain systems simultaneously. They trigger the release of dopamine, norepinephrine, and serotonin while also blocking their reuptake, which means these chemical messengers stay active in the brain longer than usual. The result is a powerful suppression of hunger signals, increased alertness, and a boost in metabolic rate. You feel less hungry, you eat less, and your body burns slightly more energy even at rest.
Recent research has clarified one of the key pathways involved. Amphetamines stimulate the secretion of a hormone called alpha-melanocyte stimulating hormone (αMSH) from the hypothalamus, the brain region that acts as a thermostat for hunger and energy balance. This hormone activates melanocortin-4 receptors, which are well known to suppress food intake. In animal studies, amphetamine elevated blood pressure and heart rate, increased heat production in brown fat tissue, and reduced both food intake and body weight through this melanocortin pathway.1PubMed Central. The metabolic and cardiovascular effects of amphetamine are partially mediated by the central melanocortin system The finding is significant because it means the appetite-suppressing and cardiovascular effects of amphetamines are partially routed through the same brain circuit, which helps explain why it has been so difficult to separate the weight-loss benefit from the heart-related risks.
The serotonin system plays a role too. Serotonin released by amphetamines appears to dampen the inhibitory norepinephrine signals that normally keep appetite-suppressing neurons in check, effectively releasing the brakes on the brain’s satiety system.2Cell Reports Medicine. Melanocortin circuitry underlies the eating-inhibitory and cardiovascular effects of amphetamine This layered mechanism, hitting dopamine reward pathways, norepinephrine-driven arousal, serotonin-mediated satiety, and hypothalamic hormone secretion all at once, is what makes amphetamines so effective at killing appetite. It is also what makes them so hard on the body.
A Brief History of Amphetamines for Weight Loss
Amphetamine was first synthesized in the late 1920s and quickly found medical uses ranging from nasal decongestion to narcolepsy treatment. By the 1940s, pharmaceutical companies had realized that the appetite-suppressing side effect could be marketed as a feature. Brightly colored combination pills, eventually dubbed “rainbow diet pills” for their varied hues, were aggressively promoted to physicians and patients across the United States. By the 1960s, these pills had caused dozens of deaths, and the FDA began pulling them from the market.3PubMed Central. The return of rainbow diet pills
The pattern repeated itself decades later. In the 1990s, the combination of fenfluramine and phentermine, marketed as “fen-phen,” became enormously popular. At its peak, millions of prescriptions were written annually. Then reports emerged linking fenfluramine to serious heart valve damage, and the drug was withdrawn in 1997. Phentermine, the other half of that combination, survived on the market and remains the most commonly prescribed short-term weight-loss medication in the United States today, though it is approved only for use lasting a few weeks.
Why the Effect Wears Off
One of the central problems with using amphetamines for weight loss is tolerance. While these drugs are potent appetite suppressants when given as a single dose or over short periods, their effectiveness diminishes with chronic use.4PubMed. The development of tolerance to drugs that suppress food intake The brain adapts to the elevated catecholamine levels by downregulating its own receptors, essentially turning down the volume on the signal. Over weeks to months, the same dose produces less appetite suppression, which tempts users to increase the dose, a pattern that accelerates the risk of dependence and side effects.
This tolerance problem is not unique to amphetamines; it affects most stimulant-class appetite suppressants. But it is particularly relevant here because it undercuts the main selling point. If you take an amphetamine for weight loss and the hunger-suppressing effect fades after a few weeks, you are left with a drug that still raises your heart rate and blood pressure but no longer helps you eat less. The risk-to-benefit ratio flips.
Cardiovascular Risks
The cardiovascular effects of amphetamines are well documented and represent the most immediate physical danger of using them for weight loss. A large Cochrane systematic review encompassing over 10,000 participants found that amphetamines increased systolic blood pressure by about 2 mmHg, diastolic blood pressure by a similar amount, and heart rate by roughly 4 beats per minute. These effects persisted even in studies lasting eight weeks or longer, indicating they are sustained rather than temporary.5PubMed Central. Effect of amphetamines on blood pressure The review concluded that people taking daily oral amphetamines face an increased risk of adverse cardiovascular events.
Those average numbers may look small, but averages obscure individual variation. Some people experience much larger spikes. Clinical trial protocols for amphetamine-based obesity treatments typically require dose reductions if blood pressure exceeds 140/90 mmHg or heart rate climbs above 100 beats per minute.6PubMed Central. A double-blind randomised controlled trial protocol comparing dexamphetamine and placebo effectiveness for obesity management in primary care settings For someone who already has high blood pressure, even modest additional strain on the cardiovascular system can push them into dangerous territory.
There is some nuance here worth noting. One study specifically tracking phentermine users over a year found that their blood pressure actually declined from baseline at all measured time points, likely because the weight loss itself lowered blood pressure enough to offset the drug’s stimulant effect.7PubMed. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity This is a real phenomenon: if you lose enough weight, your blood pressure drops, and that drop can outpace the drug-induced rise. But this defense only holds for as long as the weight stays off, and it doesn’t apply to everyone. People with pre-existing heart disease or hypertension are playing a riskier game.
The Fen-Phen Disaster and Heart Valve Damage
The most dramatic cardiovascular lesson from amphetamine-adjacent weight loss came from the fenfluramine-phentermine combination. In 1997, researchers at the Mayo Clinic reported a series of patients who developed unusual heart valve abnormalities after taking fen-phen. The valves thickened and failed to close properly, causing blood to leak backward through the heart.8PubMed. Valvular heart disease associated with fenfluramine-phentermine Some estimates put the prevalence of significant valvular disease among users as high as roughly one in four.9PubMed Central. Valvular heart disease with the use of fenfluramine-phentermine
The culprit turned out to be fenfluramine, not phentermine. Fenfluramine and its metabolite norfenfluramine activated serotonin receptors on heart valve tissue, promoting abnormal cell growth. Fenfluramine was pulled from the market, and phentermine continued to be prescribed alone. But the episode left a lasting mark on how regulators and physicians view stimulant-based weight loss drugs. It demonstrated that drugs capable of producing impressive weight loss can simultaneously cause irreversible organ damage through mechanisms that were not anticipated during initial testing.
Psychiatric and Neurological Risks
Beyond the heart, amphetamines carry meaningful psychiatric risks, especially at the doses or durations that someone pursuing weight loss might reach. A systematic review and meta-analysis found that any amphetamine use was associated with roughly double the odds of psychosis, about double the odds of violent behavior, and more than four times the odds of suicidality compared to non-users. Depression risk was also elevated.10PubMed Central. Mental health outcomes associated with of the use of amphetamines: A systematic review and meta-analysis These odds increased further among people meeting criteria for an amphetamine use disorder.
Even at prescribed doses, case reports document phentermine triggering hypomanic episodes in people with bipolar disorder and worsening depression in others.11The Primary Care Companion for CNS Disorders. Weight Loss Medication Phentermine–Induced Hypomania in Bipolar Depression Insomnia, anxiety, and irritability are common side effects at therapeutic doses, and these can erode the behavioral habits (consistent sleep, stable mood, structured eating) that are essential for sustainable weight management. In other words, the drug can undermine the very lifestyle changes it is supposed to support.
What Happens When You Stop
Rebound weight gain after stopping amphetamines is not just a matter of old habits returning. There appears to be a biological mechanism driving it. Chronic amphetamine exposure causes lasting changes in the brain’s dopamine reward circuitry. Baseline dopamine activity in key reward areas drops, and the system becomes sensitized so that stimuli like food produce exaggerated dopamine responses compared to what they would in someone who had never taken the drug.12PubMed Central. Food consumption and weight gain after cessation of chronic amphetamine administration
In practical terms, this means that after you stop taking the drug, food becomes more rewarding than it was before you started. The brain is in a state of “reward deficit,” and eating becomes one of the most accessible ways to fill that gap. Animal research shows that weight gain after amphetamine withdrawal can overshoot the original starting weight. This rebound effect is particularly cruel: you end up heavier than when you began, with a brain that has been rewired to find food more compelling than ever.
Nutritional Disruption Beyond Calories
The weight loss from amphetamines is not simply a matter of eating fewer calories and losing fat. Stimulant drugs interact with the hormonal signals that regulate appetite, including ghrelin and leptin, and can produce long-term changes in the body’s ability to detect and compensate for energy deficits. Research suggests the dietary pattern of people using stimulants is characterized by altered nutritional balance rather than a straightforward reduction in total food intake. They may eat fewer meals but shift toward nutrient-poor, calorie-dense foods when they do eat, or skip meals for extended periods and then consume large amounts at once. Over time, these disruptions in both hormonal signaling and nutrient intake can produce metabolic deficits that contribute to unhealthily low weight, muscle wasting, and micronutrient deficiencies rather than the kind of healthy fat loss most people are hoping for.
Non-Medical Use for Weight Loss
A significant number of people obtain amphetamines without a prescription specifically to lose weight. Survey data among young adults found that about 4% reported non-medical use of prescription stimulants for weight loss purposes, with more than half of those getting the drugs from friends rather than doctors.13PubMed. Non-medical use of prescription stimulants for weight loss, disordered eating, and body image People who used stimulants this way had higher levels of body image distress and eating disorder symptoms. They were also more likely to engage in other compensatory behaviors like purging or laxative use, suggesting that non-medical stimulant use for weight control tends to cluster with other harmful weight-loss practices rather than existing in isolation.
This pattern is worth understanding because it means that the people most likely to misuse amphetamines for weight loss are also the most vulnerable to their psychiatric side effects. Someone already struggling with disordered eating and body image concerns is poorly positioned to handle the mood instability, anxiety, and rebound hunger that amphetamines produce. The combination creates a vicious cycle: the drug provides temporary control over eating, stopping the drug triggers both weight gain and emotional distress, and that distress drives the person back to the drug or to other harmful behaviors.
Lisdexamfetamine and Binge Eating Disorder
There is one clinical context where an amphetamine-based drug has a legitimate and evidence-supported role related to weight: lisdexamfetamine (sold as Vyvanse) for moderate-to-severe binge eating disorder. This is not technically a weight-loss indication. The drug is approved to reduce the frequency of binge eating episodes, and weight loss occurs as a secondary effect of eating less during binges.
The evidence here is solid. A meta-analysis pooling data from three randomized controlled trials found that lisdexamfetamine significantly reduced binge eating days per week compared to placebo, with large effect sizes. Remission rates, meaning four consecutive weeks without a binge, were about two and a half times higher in the treatment group. Weight reduction was also significantly greater in the lisdexamfetamine group.14PubMed Central. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials A separate systematic review confirmed consistent evidence that lisdexamfetamine effectively reduces both binge eating symptoms and body weight in patients with the disorder.15European Neuropsychopharmacology. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder
The distinction matters. Lisdexamfetamine is a prodrug, meaning it is inactive until metabolized in the body, which gives it a slower onset and lower abuse potential than immediate-release amphetamines. It is prescribed under careful psychiatric supervision for a specific eating disorder, not handed out as a general weight-loss tool. Treating it as equivalent to using Adderall or street amphetamine to diet misrepresents both the drug and the condition it treats.
Amphetamines Versus Newer Weight-Loss Medications
The landscape of obesity pharmacotherapy has shifted dramatically with the arrival of GLP-1 receptor agonists like semaglutide and liraglutide. These newer drugs produce substantially more weight loss than older stimulant-based options, with a different side-effect profile. A systematic review comparing semaglutide, liraglutide, orlistat, and phentermine found that all had distinct benefits, but phentermine carried a notable risk of dependency that the others did not.16PubMed Central. Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review
GLP-1 drugs work through a fundamentally different mechanism. Rather than flooding the brain with catecholamines, they mimic a gut hormone that slows stomach emptying and signals fullness to the brain. They still cause side effects, primarily gastrointestinal discomfort like nausea, but they do not carry the same cardiovascular stimulant effects or abuse potential. For most patients seeking pharmacological help with obesity today, a GLP-1 agonist prescribed under medical supervision is a far more evidence-supported choice than an amphetamine. Phentermine still has a niche for short-term use when cost is a major barrier, since it is generic and cheap, but the risk-benefit calculus has shifted away from stimulants for long-term weight management.
Pregnancy and Amphetamine-Related Weight Loss Drugs
Amphetamines pose particular risks during pregnancy. Based on findings in both human populations and animal studies, prenatal amphetamine exposure increases the risk of adverse outcomes including cleft palate, cardiac anomalies, and reduced fetal growth.17PubMed. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy These risks apply even to the lower doses typical of weight-loss prescriptions, not just to illicit methamphetamine use.
Case reports illustrate the severity. One documented case involved a woman taking phentermine during the first two trimesters who delivered a child with bilateral brain cysts likely caused by a prenatal stroke.18PubMed Central. Phentermine Use During First and Second Trimesters Associated with Fetal Stroke The vasoconstricting properties of amphetamines, the same properties that raise blood pressure in adults, can restrict blood flow through the placenta and developing fetal vasculature. Anyone who is pregnant, planning to become pregnant, or who could become pregnant should not be taking amphetamine-class drugs for weight loss. This is one area where the guidance is unambiguous.
The Altered Reward System and Long-Term Consequences
Perhaps the most underappreciated risk of using amphetamines for weight loss is what they do to the brain’s relationship with food over the long term. The dopamine system changes described earlier in the context of post-discontinuation rebound are not trivial or temporary. Chronic stimulant use alters the baseline functioning of the mesolimbic dopamine pathway, the circuit that assigns motivational value to rewards like food, social interaction, and pleasurable activities. When this system is disrupted, the subjective experience of eating changes: food can become either less satisfying (during active use, contributing to the weight loss) or excessively compelling (after stopping, contributing to overshoot).
This is part of a broader pattern seen with stimulant drugs. The risks inherent to amphetamine abuse include not just weight loss and cardiovascular events but psychological dependence and structural brain changes. For someone whose goal is to reach a healthier weight and stay there, introducing a drug that fundamentally alters how the brain processes food reward is counterproductive. The initial weight loss may look like success, but the neurological aftermath can make long-term weight maintenance harder than it would have been without the drug.
None of this means amphetamines are useless in medicine. Prescribed at appropriate doses for ADHD or narcolepsy, they serve a genuine therapeutic function, and the appetite suppression is a side effect rather than the goal. But when appetite suppression is the goal, the mismatch between what amphetamines deliver in the short term and what they cost in the long term has been clear for the better part of a century. The rainbow diet pills of the 1940s, the fen-phen craze of the 1990s, and the off-label Adderall dieting of today all follow the same arc: dramatic early results, escalating risks, and outcomes that leave most users worse off than when they started.